3SBio Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jing Lou

Chief executive officer

CN¥4.5m

Total compensation

CEO salary percentage	23.1%
CEO tenure	17.6yrs
CEO ownership	2.1%
Management average tenure	no data
Board average tenure	8.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jing Lou's remuneration changed compared to 3SBio's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥4m	CN¥1m	CN¥2b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥4m	CN¥932k	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥934m
Dec 31 2020	CN¥4m	CN¥432k	CN¥836m
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥194m	CN¥432k	CN¥974m
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥6m	CN¥432k	CN¥1b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥996m
Dec 31 2017	CN¥5m	CN¥432k	CN¥935m

Compensation vs Market: Jing's total compensation ($USD617.81K) is about average for companies of similar size in the Hong Kong market ($USD584.20K).

Compensation vs Earnings: Jing's compensation has been consistent with company performance over the past year.

CEO

Jing Lou (60 yo)

17.6yrs

Tenure

CN¥4,477,000

Compensation

Dr. Jing Lou, M.D., Ph.D. is a Co-Founder of 3SBio Inc. and has been its Executive Chairman of the Board since April 1, 2012 and also serves as its Chief Executive Officer and President. Dr. Lou is Directo...

Board Members

Name	Position	Tenure	Compensation	Ownership
Jing Lou	Co-Founder	17.6yrs	CN¥4.48m	2.11% CN¥ 303.9m
Dongmei Su	Senior VP & Executive Director	11.8yrs	CN¥1.41m	1.02% CN¥ 147.5m
Bin Huang	Non-Executive Director	9.4yrs	CN¥696.00k	1.35% CN¥ 194.8m
Dan Zhang	Independent Non-Executive Director	1.3yrs	no data	no data
Tianruo Pu	Independent Non-Executive Director	8.8yrs	CN¥258.00k	no data
Hoi Ti Yang	Independent Non-Executive Director	2.8yrs	CN¥258.00k	no data
Joo Yeow Ng	Independent Non-Executive Director	2.3yrs	CN¥244.00k	no data

8.8yrs

Average Tenure

58yo

Average Age

Experienced Board: 1530's board of directors are considered experienced (8.8 years average tenure).

3SBio Management

Management criteria checks 3/4

Key information

Recent management updates

3Sbio Inc. Announces Management Changes

3SBio Inc., Annual General Meeting, Jun 25, 2024

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Recent updates

3Sbio Inc. Announces Management Changes

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Mandi Foam of 3SBio Inc. Approves for Market Launch

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.40 in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: EPS: CN¥0.78 (vs CN¥0.65 in FY 2021)

Now 22% undervalued

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020)

3SBio Inc., Annual General Meeting, Jun 22, 2022

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

3SBio Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

3Sbio Inc. Announces Completion the Enrolment of Subjects for Phase Ii Clinical Study

New 90-day high: HK$8.42

3SBio Inc. Provides Update on License Agreement with AstraZeneca and Hongkong Sansheng

New 90-day high: HK$7.81

New 90-day low: HK$7.06

3Sbio Inc. Receives Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-212

New 90-day low: HK$7.19

New 90-day low: HK$8.13

First half earnings released

New 90-day low: HK$8.22

3SBio Inc. to Report First Half, 2020 Results on Aug 17, 2020

New 90-day low - HK$8.98

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age